First Author: C.Kucukerdonmez TURKEY
Co Author(s): E. Cinar M.O. Zengin S. Selim E.T. Erakgun 0 0 0 0 0 0 0 0 0
Back to previous
To assess the anatomical and functional outcomes of intravitreal dexamethasone implant(Ozurdex®) in patients with refractory macular edema (ME) secondary to retinitis pigmentosa(RP).
Six eyes of 4 patients (3 female,1 male; aged between 9 to 39 years) diagnosed with RP who had ME and were unresponsive to carbonic anhydrase treatment were enrolled.
Baseline clinical examination included best-corrected visual acuity(BCVA), IOP measurement, biomicroscopy, and fundus examination. The central macular thickness(CMT) of all patients were measured using spectral-domain OCT(Spectralis,Heidelberg) at the baseline, first week, first, third and sixth months after intravitreal dexamethasone implant injection. The clinical outcomes and adverse events were recorded.
All patients completed the six months follow-up. The baseline median CMT was found 532μm (range,436-576μm) which decreased to 349μm (range 270-500μm) at 1 month, 342μm (range,279-500μm) at 3 months, and 470μm (range, 310-727μm) at 6 months after injection. Also, the median BCVA(logMAR) improved from 0.5(range,0.2-0.7) at the baseline, to 0.25(range,0.1-0.5) at 1 month, and to 0.2(range,0.1-0.4) at 3 months after injection. Macular edema recurred in 4 eyes at six months, however, the BCVA did not change(2 eyes) or remained increased(2 eyes) compared with the baseline. BCVA decreased in only one eye at sixth month, who had no recurrence of macular edema. No significant ocular or systemic side effects occured after intravitreal injection of Ozurdex during the follow-up period.
Our study results demonstrated that intravitreal dexamethasone implant offers anatomic and visual improvement in treatment of refractory ME secondary to RP.